Hana Passes Zensana Development To Par
This article was originally published in The Pink Sheet Daily
Executive Summary
Deal valued at up to $50 million will allow Hana to proceed with development of oncology candidates, Hana said.
You may also be interested in...
Talon May Soon Have First Marqibo Approval In Its Grasp
Biotech formerly known as Hana Biosciences submits NDA for the nano-encapsulated vincristine for use as salvage in adults with Ph- ALL.
Talon May Soon Have First Marqibo Approval In Its Grasp
Biotech formerly known as Hana Biosciences submits NDA for the nano-encapsulated vincristine for use as salvage in adults with Ph- ALL.
No Simple Fix For Precipitate Problem; Hana Withdraws Zensana NDA
Hana also drops its SPA request for Marqibo, citing a change in FDA policy on open-label oncology trials.